PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR APPLICATION Russian patent published in 2021 - IPC C07D233/64 C07D233/68 C07D233/90 C07D405/10 A61K31/4174 A61P1/04 A61P1/16 A61P11/06 A61P13/10 A61P13/12 A61P17/00 A61P17/02 A61P17/06 A61P17/14 A61P19/02 A61P21/00 A61P21/04 A61P25/28 A61P27/02 A61P27/06 A61P29/00 A61P35/00 A61P37/02 

FIELD: organic chemistry.

SUBSTANCE: invention relates to the field of organic chemistry, namely, to a heterocyclic compound of Formula (I) or to its pharmacologically acceptable salt, wherein L is (CH₂)₅, which is optionally substituted with one methyl group; R¹ is hydrogen; R² is halogen, CN, C₁–C₄-haloalkyl, C₁–C₄-haloalkoxy or furanyl; R³ is С₁-C₄-haloalkyl, -CN or halogen. Invention also relates to (3R)-6-(2-((2-(4-chlorophenyl)-5-(trifluoromethyl)-1H-imidazol-1-yl) methyl) phenoxy)-3-methylhexanoic acid, (R)-6-(2-((5-chlorine-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)-3-methylhexanoic acid, (R)-6-(2-((2-(4-cyanophenyl)-5-(trifluoromethyl)-1H-imidazol-1-yl)methyl)phenoxy)-3-methylhexanoic acid, (3R)-3-methyl-6-(2-((5-(trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoic acid or their pharmaceutically acceptable salts, a pharmaceutical composition based on a compound of Formula (I) or specific compounds mentioned above, a method of treating a PPAR δ -associated disease or condition in a subject, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula (I) or specific compounds mentioned above.

EFFECT: new heterocyclic compounds useful for treatment of PPARδ -associated diseases have been obtained.

(I)

15 cl, 1 tbl, 11 ex